Evidence map›Paper›PMID 36275644›Full record

ArticleFrontiers in immunology2022

A novel cell senescence-related IncRNA survival model associated with the tumor immune environment in colorectal cancer.

Chengfei Xu, Fanghan Li, Zilin Liu, Chuanjing Yan, Jiangwei Xiao

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Chengfei XuDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu Medical College, Chengdu, China.
Fanghan LiDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu Medical College, Chengdu, China.
Zilin LiuDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu Medical College, Chengdu, China.
Chuanjing YanDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu Medical College, Chengdu, China.
Jiangwei XiaoDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu Medical College, Chengdu, China.
First Affiliated Hospital of Chengdu Medical College · CNChengdu Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long noncoding RNAs have a major role in tumorigenesis, development, and metastasis in colorectal cancer (CRC), participate in the regulation of cell senescence and are related to the prognosis of CRC. Therefore, it is important to validate cell senescence-related lncRNAs that correlate with prognosis in CRC. Methods: CRC expression profile data and clinical information were downloaded from TCGA. A gene list related to cellular senescence was obtained from Human Aging Genomic Resources. A coexpression network of cell senescence-related mRNA-lncRNA was explored with R. Six cell senescence-related lncRNA signatures were identified by univariate and multivariate analyses. The cell senescence-related risk model was generated by using six cell senescence-related lncRNAs, and the risk score was calculated. Furthermore, an internal validation set and GSE17537 were used to verify the risk model. The risk model demonstrated good stability and accuracy. Finally, we investigated the correlation between cell senescence-related risk scores and immune infiltration, immune function, immune checkpoints, and drug sensitivity. Result: We established a signature of six cell senescence-related lncRNAs. The cell senescence-related risk model revealed an exceptional ability to assess the prognosis of colorectal cancer and was correlated with clinical features. Additionally, we observed that risk models correlate with the tumor microenvironment and immune checkpoints, potentially predicting patient response to clinical immunotherapy. Finally, we validated the correlation between the cell senescence-related risk model and drug susceptibility. Our findings indicated that AICAR, cisplatin, nilotinib, and bexarotene exhibited lower IC50 values in the high-risk group. Conclusion: Our current study identified 6 cell senescence-associated lncRNA signatures that may be vital biomarkers to predict the prognostic features and immune and chemotherapy responses in CRC.

Indexed as

Colorectal NeoplasmsRNA, Long NoncodingBexaroteneBiomarkers, TumorCellular SenescenceCisplatinGene Expression Regulation, NeoplasticHumansRNA, MessengerTumor MicroenvironmentBexaroteneBiomarkers, TumorCisplatinRNA, Long NoncodingRNA, Messengercell senescencecolorectal cancerimmune cell infiltratelong non-coding RNAs(lncRNAs)survival analysissurvival model.

Identifiers

PMID36275644
PMCPMC9583265
OpenAlexW4302287176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.